CCL26

Chr 7

C-C motif chemokine ligand 26

Also known as: IMAC, MIP-4a, MIP-4alpha, SCYA26, TSC-1

NCBI Gene: 10344ENSG00000006606UniProt: Q9Y258

This gene is one of two Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 7. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for normal peripheral blood eosinophils and basophils. This protein also has antimicrobial activity, displaying an antibacterial effect on S. pneumoniae, S. aureus, Non-typeable H. influenzae, and P. aeruginosa. The product of this gene is one of three related chemokines that specifically activate chemokine receptor CCR3. This chemokine may contribute to the eosinophil accumulation in atopic diseases. [provided by RefSeq, Jul 2020]

57
ClinVar variants
26
Pathogenic / LP
0.01
pLI score
1
Active trials
Clinical Summary— CCL26
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.01) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
26 Pathogenic / Likely Pathogenic· 27 VUS of 57 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.75LOEUF
pLI 0.010
Z-score 0.36
OE 0.80 (0.35–1.75)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.20Z-score
OE missense 1.08 (0.87–1.35)
55 obs / 50.9 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.80 (0.35–1.75)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.08 (0.87–1.35)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.96
0≤1.21.6
LoF obs/exp: 3 / 3.8Missense obs/exp: 55 / 50.9Syn Z: 0.15

ClinVar Variant Classifications

57 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic22
Likely Pathogenic4
VUS27
Likely Benign4
22
Pathogenic
4
Likely Pathogenic
27
VUS
4
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
22
0
22
Likely Pathogenic
0
0
4
0
4
VUS
0
10
17
0
27
Likely Benign
0
2
1
1
4
Benign
0
0
0
0
0
Total01244157

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CCL26 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E et al.·J Allergy Clin Immunol
2019Clinical trial
Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council.
Renert-Yuval Y et al.·J Allergy Clin Immunol
2021Review
Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.
Bangert C et al.·Nat Commun
2024
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Guttman-Yassky E et al.·Allergy
2024Clinical trial
Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS.
McEachin ZT et al.·Cell
2025
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Hamilton JD et al.·J Allergy Clin Immunol
2014Clinical trial
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Guttman-Yassky E et al.·Allergy
2024Clinical trial
Manuka honey activates the aryl hydrocarbon receptor: Implications for skin inflammation.
Alangari AA et al.·Pharmacol Res
2023
Transcriptomic profiling of vitiligo patients shows polar immune dysregulation in involved and uninvolved skin.
Brunner PM et al.·J Allergy Clin Immunol
2025Cohort
IL-13-induced STAT3-dependent signaling networks regulate esophageal epithelial proliferation in eosinophilic esophagitis.
Marella S et al.·J Allergy Clin Immunol
2023
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
CCL26-CX3CR1 Axis Mediates a Feedback Loop between Cancer Cell and PMN-MDSCs to Promote CD8+ T Cell Exhaustion during Stomach Carcinogenesis.
Jiang X et al.·Research (Wash D C)
2025🔓 Open Access
Changes and Diagnostic Value of Serum CCL26 and CCR3 in T2DM with Lower Extremity Artery Disease.
Zhang X et al.·Vasc Health Risk Manag
2025🔓 Open Access
CCL26 and CXCL12 preserve insulin-sensitizing macrophages in subcutaneous adipose tissue in obesity.
Jeelani I et al.·Cell Rep
2025
Predictive value of CCL26 and CCR3 levels for prognosis assessment in children with Mycoplasma pneumoniae pneumonia treated with azithromycin.
Ma L et al.·Transl Pediatr
2025🔓 Open Access
Inhibition of IL-4Rα reduces CCL26 in bronchial epithelial cells from COPD patients.
Pesic J et al.·ERJ Open Res
2025🔓 Open AccessCohort
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
Chronic Obstructive Pulmonary Disease Exacerbation

The CATALINA Study

RECRUITING
NCT05008081Wim JanssensStarted 2022-10-25

External Resources

Links to major genomics databases and tools